Additionally, Xinermei, a GLP-1-based weight-loss drug independently developed by Innovent Biologics, was approved for marketing in China in June 2025
Again, body weight and food intake were monitored once daily in the afternoon
Interestingly, while GLP-1-expressing NTS neurons also project to the ventral striatum [102] and administration of exendin-4 into this brain region reduces food intake and the motivation to obtain a food reward [100, 102], this treatment does not affect ventral striatal dopamine release [103]
This estimate was based on a poll of plaintiffs lawyers, revealing around 7,000 potential cases currently under investigation
Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy